Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUM-101 Malaria Vaccine in Healthy Children and Infants in Burkina Faso
NCT06618885Phase 1Completed
- Sponsor
- European Vaccine Initiative
- Start
- Aug 2025
- Primary completion
- Jan 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SUM-101 in malaria (2 arms), sponsored by European Vaccine Initiative. Primary endpoints: Local and systemic solicited adverse events, Local and systemic unsolicited reactogenicity adverse events and 2 more. Started Aug 2025; status: completed.
02
Drugs
SUM-101
03
Conditions
malaria
Beyond the preview
Go deeper on NCT06618885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06618885.